Shi et al. showed that a novel GLP-1/GIP receptor dual agonist (DA-JC4) ameliorates cognitive decline by resensitizing insulin signaling, altering the inflammatory response, and reducing the ratio of pro-apoptotic BAX to anti-apoptotic Bcl-2 levels in streptozotocin (STZ)-induced AD rats [157]. The gene discussed is BCL2; the disease is Alzheimer disease.